Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 2, 2003, Pages 265-270

  Favennec, L ^a   Jave Ortiz, J ^b   Gargala, G ^a   Lopez Chegne, N ^b   Ayoub, A ^c   Rossignol, J F ^c  

^a UNIVERSITÉ DE ROUEN   (France)

^b Hospital General de Cajamarca   (Peru)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; BITHIONOL; COLUFASE; NITAZOXANIDE; PLACEBO; PRAZIQUANTEL; TRICLABENDAZOLE;

ABDOMINAL PAIN; ADULT; AMENORRHEA; APPETITE DISORDER; ARTICLE; ASTHENIA; BRONCHUS OBSTRUCTION; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPISTAXIS; FASCIOLA HEPATICA; FASCIOLIASIS; FECES ANALYSIS; FEMALE; FEVER; HEADACHE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PAIN; PARASITE; PERU; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINE COLOR;

ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FASCIOLIASIS; FEMALE; HUMANS; MALE; THIAZOLES; TREATMENT OUTCOME;

EID: 0242600803     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01419.x     Document Type: Article

References (12)

1. Chen MG, Mott KE. Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Trop Med Bull 1990; 87: R2-37.
2. Gilles HM. Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 2002; 18: 95-7.
3. Rossignol JF. Hidalgo H, Feregrino M. et al. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients. Trans R Soc Trop Med Hyg 1998; 92: 663-6.
4. Rossignol JF, Ayoub A, Ayers M. Treatment of diarrhoea caused by Cryptosporidium parvum: a prospective randomized double-blind placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184: 103-6.
5. Rossignol JF, Ayoub A, Ayers M. Treatment of diarrhoea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184: 381-4.
6. Jave-Ortiz J, Ayoub A, Gargala G, Lopez-Chegne N, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment Pharmacol Ther 2001; 15: 1409-15.
7. Jave-Ortiz J, Chegne NL, Gargala G, Favennec L. Comparative clinical study of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis. Trans R Soc Trop Med Hyg 2002; 96: 1-4.
8. Abdel-Rahman MS, El-Bahy MM, El-Bahy NM. Testing the parasiticidal efficacy of nitazoxanide. Alex J Vet Sci 1997; 13: 447-58.
9. Broekhuysen J, Stockis A, Lins RL, De Graeve J. Rossignol JF. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharm Ther 2000; 38: 387-94.
10. Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 1998; 92: 103-4.
11. Millan JC. Mull R. Freise S, Richter J. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63: 264-9.
12. Robinson MW, Trudgett A, Hoey EM. Fairweather I. Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Parasitology 2000; 124: 325-38.